Melatonin synergized with cyclosporine A improves cardiac allograft survival by suppressing inflammation and apoptosis

Liu,Chen; Hong,Tao; Shao,Mengping; Chen,Zhenghang; Wang,Chunsheng

doi:10.3892/mmr.2014.2382

Melatonin synergized with cyclosporine A improves cardiac allograft survival by suppressing inflammation and apoptosis

Authors:
- Chen Liu
- Tao Hong
- Mengping Shao
- Zhenghang Chen
- Chunsheng Wang
View Affiliations

Affiliations: Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
Published online on: July 15, 2014 https://doi.org/10.3892/mmr.2014.2382
Pages: 1323-1328

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melatonin, a widespread physiological mediator, has been demonstrated to exhibit a dose‑dependent immunoregulatory effect in vitro and in vivo, including mediating physiological circadian rhythms, neutralizing free radicals and exerting antisenescence actions. In the present study, the efficacy and mechanism of melatonin alone or in combination with cyclosporine (CsA) in prolonging heart transplantation survival was examined. Daily treatment with melatonin (200 mg/kg/day) through a gavage, significantly prolonged the survival of cardiac grafts (mean survival time, 13.4±2.4 days; n=7; P<0.0001) compared with the untreated controls (5.8±1.2 days; n=7). When CsA (5 mg/kg/day) was co‑administered with melatonin (50 mg/kg/day), the survival rate improved (31.6±2.4 days; n=7; P<0.001), compared with that achieved by only 20 mg/kg/day CsA (22±2.8 days; n=7). As expected, melatonin significantly alleviated the inflammatory response and apoptosis as determined by TdT‑mediated dUTP‑biotin nick end labeling assay (P<0.05). Further analysis demonstrated that melatonin significantly reduced p65 activation and the release of inflammatory factors. Therefore, these findings indicate that melatonin in combination with CsA protected the cardiac allograft by inhibiting inflammation‑induced apoptosis. These results provide evidence for a novel therapeutic approach for future immunosuppressive agents in organ transplantation.

View Figures

View References

1	Gill JS: Cardiovascular disease in transplant recipients: current and future treatment strategies. Clin J Am Soc Nephrol. 3(Suppl 2): S29–S37. 2008. View Article : Google Scholar : PubMed/NCBI
2	Bruschi G, Colombo T, Oliva F, et al: Heart transplantation: 25 years’ single-centre experience. J Cardiovasc Med (Hagerstown). 14:637–647. 2013.
3	Fiorelli AI, Branco JN, Dinkhuysen JJ, et al: Risk factor analysis of late survival after heart transplantation according to donor profile: a multi-institutional retrospective study of 512 transplants. Transplant Proc. 44:2469–2472. 2012. View Article : Google Scholar
4	Suzuki J, Ogawa M, Hirata Y, Nagai R and Isobe M: Effects of immunoglobulin to prevent coronary allograft vasculopathy in heart transplantation. Expert Opin Ther Targets. 16:783–789. 2012. View Article : Google Scholar
5	Tedoriya T, MacDonald PS, Keogh AM, Wilson M and Spratt PM: Reversal of chronic cyclosporin nephrotoxicity after heart transplantation. J Heart Lung Transplant. 20:247–248. 2001. View Article : Google Scholar : PubMed/NCBI
6	Aumente MD, Arizón JM, Segura J, et al: Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. Transplant Proc. 37:4014–4017. 2005. View Article : Google Scholar
7	Baan CC, Vaessen LM, Balk AH, et al: Cyclosporin A sensitivity of allo-specific precursor and committed cytotoxic T lymphocytes after clinical heart transplantation. Transplant Proc. 26:2849–2851. 1994.PubMed/NCBI
8	Werkö L: Cyclosporin as a cause of hypertension in patients with heart transplantation. Lakartidningen. 88:5031991.(In Swedish).
9	Huang XP, Sun Z, Miyagi Y, et al: Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation. 122:2419–2429. 2010. View Article : Google Scholar : PubMed/NCBI
10	Espino J, Pariente JA and Rodríguez AB: Oxidative stress and immunosenescence: therapeutic effects of melatonin. Oxid Med Cell Longev. 2012:6702942012. View Article : Google Scholar : PubMed/NCBI
11	Fildes JE, Yonan N and Keevil BG: Melatonin - a pleiotropic molecule involved in pathophysiological processes following organ transplantation. Immunology. 127:443–449. 2009. View Article : Google Scholar
12	Gilad E, Wong HR, Zingarelli B, et al: Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. Faseb J. 12:685–693. 1998.PubMed/NCBI
13	Jung FJ, Yang L, Härter L, et al: Melatonin in vivo prolongs cardiac allograft survival in rats. J Pineal Res. 37:36–41. 2004. View Article : Google Scholar : PubMed/NCBI
14	Cardell M, Jung FJ, Zhai W, et al: Acute allograft rejection and immunosuppression: influence on endogenous melatonin secretion. J Pineal Res. 44:261–266. 2008. View Article : Google Scholar : PubMed/NCBI
15	Eşrefoğlu M1, Kuruş M and Sahna E: The beneficial effect of melatonin on chronic cyclosporin A nephrotoxicity in rats. J Int Med Res. 31:42–44. 2003.PubMed/NCBI
16	Rezzani R, Buffoli B, Rodella L, Stacchiotti A and Bianchi R: Protective role of melatonin in cyclosporine A-induced oxidative stress in rat liver. Int Immunopharmacol. 5:1397–1405. 2005. View Article : Google Scholar : PubMed/NCBI
17	Yoo YM and Jeung EB: Melatonin suppresses cyclosporine A-induced autophagy in rat pituitary GH3 cells. J Pineal Res. 48:204–211. 2010. View Article : Google Scholar : PubMed/NCBI
18	Jessup M, Banner N, Brozena S, et al: Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. J Heart Lung Transplant. 25:1003–1023. 2006.
19	Carrillo-Vico A, Lardone PJ, Naji L, et al: Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res. 39:400–408. 2005. View Article : Google Scholar
20	Santello FH, Frare EO, Caetano LC, AlonsoToldo MP and do Prado JC Jr: Melatonin enhances pro-inflammatory cytokine levels and protects against Chagas disease. J Pineal Res. 45:79–85. 2008. View Article : Google Scholar : PubMed/NCBI
21	Tang EH, Libby P, Vanhoutte PM and Xu A: Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J Cardiovasc Pharmacol. 59:116–123. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wolters SL, Corsten MF, Reutelingsperger CP, Narula J and Hofstra L: Cardiovascular molecular imaging of apoptosis. Eur J Nucl Med Mol Imaging. 34(Suppl 1): S86–S98. 2007. View Article : Google Scholar : PubMed/NCBI
23	Szabolcs M, Michler RE, Yang X, et al: Apoptosis of cardiac myocytes during cardiac allograft rejection. Relation to induction of nitric oxide synthase. Circulation. 94:1665–1673. 1996. View Article : Google Scholar : PubMed/NCBI
24	Gedik HS, Korkmaz K, Erdem H, Karakilic E, Lafci G and Ankarali H: Protective effect of heparin in the end organ ischemia/reperfusion injury of the lungs and heart. J Cardiothorac Surg. 7:1232012. View Article : Google Scholar : PubMed/NCBI